Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The ATLAS2 (Anti-psychotic Treatment of very LAte onset Schizophrenia like psychosis) is a double-blind randomised trial that aims to provide reliable evidence on whether giving a low dose of amisulpride, an antipsychotic-drug, to people with a diagnosis of late onset psychosis produces sufficient benefit to outweigh the potential risks. ATLAS volunteers will be randomly allocated to take either amisulpride 100mg or matching placebo for 12 weeks with a second randomisation to switch or to continue with the same treatment for a further 12 weeks. The ATLAS trial design ensures that all participants will receive amisulpride for at least 12 weeks of that time. Late onset psychosis is a common condition with a large adverse effect on the quality of life of those affected.  Yet, currently, there are no randomised clinical trial data to inform treatment of this large but understudied group of patients.

ATLAS is funded by the NIHR Health Technology Assessment programme (HTA) and aims to recruit 100 patients, a small number compared to the many tens of thousands of future patients, whose treatment will be guided by the results of the ATLAS study.

Please contact for any further information.

Related research themes